Indian Science Cruiser

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Bacteria –The New ‘magic Bullet’ Against Cancer!


Affiliations
1 Department of Biotechnology
2 Department of Microbiology, St. Xavier’s College (Autonomous), 30, Mother Teresa Sarani, Kolkata -700 016, West Bengal, India
     

   Subscribe/Renew Journal


Microbes in general, as also the commensal human microbiota, are an important modulator of disease physiology of the host, including affecting cancer proliferation and progression. Cancer metastasis still remains an enigma in origin and consequence, and is one of the most important causes of morbidity and mortality of man in the recent times. A myriad of beneficial immunological effects, including the highly important anti-cancer activities, have been attributed to some specific bacteria, as also some members of the human normal microflora. Even though there is no direct experimental evidence as of now, in support of cancer suppression as a result of microbial infestation in the human body, yet, there is a wealth of indirect evidence available in the literature, which is based largely on laboratory studies, and those will grossly be revisited in the present paper. As bacteria-mediated tumour therapy (BMTT) has ample potential to evolve into the much desired ‘magic bullet’ against various types of malignancies, this paper aims to present a state-of-the-art review on applicability of bacteria as cancer therapeutics. Further, this review will delineate the selective advantages of BMTT over the conventional chemotherapeutic drugs against cancer, and will also discuss the associated challenges ahead.

Keywords

Commensal Human Microbiota, Cancer Metastasis, BMTT, Magic Bullet, Malignancies, Cancer Therapeutics.
User
Subscription Login to verify subscription
Notifications
Font Size

  • R. Koch UntersuchungenüberBakterien: V. Die Atiologie der Milzbrand-Krankheit, begründet auf die Entwicklungsgeschichte des Bacillus anthracis. CohnsBeitragezurBiologie der Pflanzen. 1876; 2(2):277-310.

  • DJ. Grimes Koch’s Postulates—Then and Now. Microbe. 2006; 1(5):223-228.

  • RA. Weinberg Biology of Cancer, 2nd Edition (Garland Science). 2007.

  • J. Parsonnet Bacterial Infection as a Cause of Cancer. Environ Health Perspect. 1995; 103:263-268.

  • E. Velazqueza A. Peixb, and A. Gomez-Alonso Microorganisms and cancer: Scientific evidence and new hypotheses. Cirugía Española (English Edition). 2011; 89(3):136-144.

  • S Felgner, D Kocijancic, M Frahm, and S. Weiss Bacteria in Cancer Therapy: Renaissance of an Old Concept. Int J Microbiol. 2016; 8451728.

  • S Felgner, V Pawar, D Kocijancic, M Erhardt, and Weiss S.Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome. Microb Biotechnol. 2017; 10(5):1074-1078.

  • B Umer, D Good, J Anné, W Duan, and Wei MQ. Clostridial spores for cancer therapy: targeting solid tumour microenvironment. J Toxicol. 2012; 862764.

  • S Liu, X Xu, X Zeng, L Li, Q Chen, and J. Li Tumor‑targeting bacterial therapy: A potential treatment for oral cancer (Review). Oncol Lett. 2014; 8:2359-2366.

  • G Housman, S Byler, S Heerboth, K Lapinska, M Longacre, N Snyder and S. Sarkar Drug resistance in cancer: an overview. Cancers (Basel). 2014; 6(3):1769-1792.

  • FJ. Esteva Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer. The Oncologist. 2004; 9.

  • B Alberts, A Johnson, J Lewis, D Morgan, M Raff, K Roberts, and P. Walter Molecular Biology of the Cell, 6th Edition (Garland Science). 2015.

  • F Sabzehali, H Azimi, and M. Goudarzi Bacteria as a vehicle in cancer therapy and drug delivery. J Paramed Sci. 2017; 8(1).

  • S Bashiardes, T Tuganbaev, S Federici and E. Elinav The microbiome in anti-cancer therapy. Semin Immunol. 2017; 32:74-81.

  • NS Forbes Profile of a bacterial tumor killer. Nat Biotechnol. 2006; 24:1484‑1485.

  • HC Nauts, WE Swift, and BL Coley. The Treatment of Malignant Tumors by Bacterial Toxins as Developed by the Late William B. Coley, M.D., Reviewed in the Light of Modern Research. Cancer Res. 1946; 6:205-216.

  • M Sznol, L. Stanley Lin, David Bermudes, Li-mou Zheng, and I. King Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest. 2000; 105(8):1027–1030.

  • LH Dang, C Bettegowda, DL Huso, KW Kinzler and B. Vogelstein Combination bacteriolytic therapy for the treatment of experimental tumors. PNAS. 2001; 98(26):15155-15160.

  • CA Hunter, D Yu, M Gee, CV Ngo, C Sevignani, M Goldschmidt, TV Golovkina, S Evans, WF Lee and A. Thomas-Tikhonenko Cutting Edge: Systemic Inhibition of Angiogenesis Underlies Resistance to Tumors During Acute Toxoplasmosis. J Immunol. 2001; 166(10):5878-5881.

  • A Darzins, and AM. Chakrabarty Cloning of genes controlling alginate biosynthesis from a mucoid cystic fibrosis isolate of Pseudomonas aeruginosa. J Bacteriol. 1984; 159(1):9-18.

  • T Yamada, M Goto, V Punj, O Zaborina, ML Chen, K Kimbara, D Majumdar, E Cunningham, TK Das Gupta, and AM. Chakrabarty Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. PNAS. 2002; 99(22):14098-14103.

  • T Yamada, Y Hiraoka, M Ikehata, K Kimbara, BS Avner, TK Das Gupta, and AM Chakrabarty. Apoptosis or growth arrest: Modulation of tumor suppressor p53’s specificity by bacterial redox protein azurin. PNAS. 2004; 101(14):4770-4775.

  • P Chorobik, D Czaplicki, K Ossysek, and J. Bereta Salmonella and cancer: from pathogens to therapeutics. ActaBiochim Pol. 2013; 60(3):285–297.

  • JH Zheng, VH Nguyen, S-N Jiang, S-H Park, W Tan, SH Hong, MG Shin, IJ Chung et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci Transl Med. 2017; 9(376):1-10.

  • A Sivan, L Corrales, N Hubert, JB Williams, K Aquino-Michaels, ZM Earley, FW Benyamin, YM Lei, B Jabri, M-L Alegre, EB Chang and TB Gajewski. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science. 2005; 350(6264):1084-1089.

  • RD Lardone, AA Chan, AF Lee, LJ Foshag, MB Faries, PA Sieling and DJ. Lee Mycobacterium bovis Bacillus Calmette–Guerin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function. Front Immunol. 2017; 8:965.

  • M Tangney and CGM. Gahan Listeria monocytogenes as a Vector for Anti-Cancer Therapies. Curr Gene Ther. 2010; 10(1):46-55.

  • L Zhong, X Zhang, and M. Covasa Emerging roles of lactic acid bacteria in protection against colorectal cancer. World J Gastroenterol. 2014; 20(24):7878-7886.

  • K Hirayama and J. Rafter The role of probiotic bacteria in cancer prevention. Microbes Infect. 2000; 2(6):681-686.

  • BL Pool-Zobel, C Neudecker, I Domizlaff, S Ji, U Schillinger, C Rumney, M Moretti, I Vilarini, R Scassellati-Sforzolini and I. Rowland Lactobacillus-and Bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr Cancer. 1996; 26(3):365-380.

  • S Patyar, R Joshi, DS Byrav, A Prakash, B Medhi, and BK. Das Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci. 2010; 17(1):21.

  • L Sanchez-Garcia, L Martín, M Ramon, Neus Ferrer-Miralles, V Esther and V. Antonio Recombinant pharmaceuticals from microbial cells: a 2015 update. Microb Cell Fact. 2015; 15:33.

  • S Geisse, H Gram, B Kleuser, and HP. Kocher Eukaryotic Expression Systems: A Comparison. Prot. Expr. Purif. 1996; 8(3):271-282.

  • R Mercado-Lubo, Y Zhang, L Zhao, K Rossi, X Wu, Y Zou, A Castillo, J Leonard, R Bortell, DL Greiner, LD Shultz, G Han and BA. McCormick A Salmonella nanoparticle mimic overcomes multidrug resistance in tumours. Nat Commun. 2016; 7:12225.

  • T Danino, A Prindle, GA Kwong, M Skalak, H Li, K Allen, J Hasty and SN. Bhatia Programmable probiotics for detection of cancer in urine. Sci Transl Med. 2015; 7(289):289.

  • Yu YA, S Shabahang, TM Timiryasova, Q Zhang, R Beltz, I Gentschev et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol. 2004; 22:313–320.


Abstract Views: 611

PDF Views: 5




  • Bacteria –The New ‘magic Bullet’ Against Cancer!

Abstract Views: 611  |  PDF Views: 5

Authors

Souvik Roy
Department of Biotechnology
Lopamudra Roy
Department of Microbiology, St. Xavier’s College (Autonomous), 30, Mother Teresa Sarani, Kolkata -700 016, West Bengal, India
Nilanjan Das
Department of Biotechnology

Abstract


Microbes in general, as also the commensal human microbiota, are an important modulator of disease physiology of the host, including affecting cancer proliferation and progression. Cancer metastasis still remains an enigma in origin and consequence, and is one of the most important causes of morbidity and mortality of man in the recent times. A myriad of beneficial immunological effects, including the highly important anti-cancer activities, have been attributed to some specific bacteria, as also some members of the human normal microflora. Even though there is no direct experimental evidence as of now, in support of cancer suppression as a result of microbial infestation in the human body, yet, there is a wealth of indirect evidence available in the literature, which is based largely on laboratory studies, and those will grossly be revisited in the present paper. As bacteria-mediated tumour therapy (BMTT) has ample potential to evolve into the much desired ‘magic bullet’ against various types of malignancies, this paper aims to present a state-of-the-art review on applicability of bacteria as cancer therapeutics. Further, this review will delineate the selective advantages of BMTT over the conventional chemotherapeutic drugs against cancer, and will also discuss the associated challenges ahead.

Keywords


Commensal Human Microbiota, Cancer Metastasis, BMTT, Magic Bullet, Malignancies, Cancer Therapeutics.

References





DOI: https://doi.org/10.24906/isc%2F2018%2Fv32%2Fi6%2F180788